Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as liposomal doxorubicin, work in different ways to stop the growth of cancer cells, either
by killing the cells or by stopping them from dividing. Giving rituximab together with
liposomal doxorubicin may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects of giving rituximab together with
liposomal doxorubicin and to see how well they work in treating patients with relapsed or
refractory B-cell non-Hodgkin's lymphoma.